Abstract:AMV@NanoCip, a novel biomimetic nanomedicine, integrates PBP2a antibody‐presenting nanovesicles with self‐assembled ciprofloxacin nanoparticles exhibiting sonodynamic properties. This formulation demonstrates exceptional MRSA‐targeting and antibacterial efficacy, achieving 99.99% sterilization in vitro and significant bacterial reduction in a pneumonia model. The sequential treatment strategy, combining adhesion, membrane disruption, and synergistic therapy, presents a promising approach for combating bacterial infections. Bacterial‐induced lower respiratory tract infections are a growing global health concern, exacerbated by the inefficacy of conventional antibiotics and delivery methods to effectively target the lower respiratory tract, leading to suboptimal therapeutic outcomes. To address this challenge, this work engineers PBP2a antibody‐presenting membrane nanovesicles (AMVs) specifically designed to target the penicillin‐binding protein variant on the surface of methicillin‐resistant Staphylococcus aureus (MRSA). Concurrently, this work develops pure ciprofloxacin nanoparticles (NanoCip) that, for the first time, exhibits exceptional self‐generated sonodynamic properties, attributed to hydrogen‐bond‐driven self‐assembly, while maintaining their inherent pharmacological efficacy. These NanoCip particles are integrated with AMVs to create a novel biomimetic nanomedicine, AMV@NanoCip. This formulation demonstrated remarkable MRSA‐targeting affinity in both in vitro and in vivo models, significantly enhancing antibacterial activity. Upon ultrasound stimulation, AMV@NanoCip achieves over 99.99% sterilization of MRSA in vitro, with a reduction exceeding 5.14 Log CFU. Prokaryotic transcriptomic analysis further elucidates the synergistic mechanisms by which AMV@NanoCip, coupled with ultrasound, disrupts the MRSA exoskeleton. In a MRSA‐induced pneumonia animal model, AMV@NanoCip+US results in a substantial bacterial load reduction in the lungs (99.99%, 4.02 Log CFU). This sequential treatment strategy (adhesion‐membrane disruption‐synergistic therapy) offers significant promise as an innovative therapeutic approach for combating bacterial infections.

Tobramycin-mediated self-assembly of DNA nanostructures for targeted treatment of Pseudomonas aeruginosa-infected lung inflammation

Ultrasound-Launched Targeted Nanoparticle Enhances Antibacterial Sonodynamic Therapy for Effective Eradication of Pseudomonas Aeruginosa Biofilm

Ultrasound-Activatable Phase-Shift Nanoparticle As a Targeting Antibacterial Agent for Efficient Eradication Ofpseudomonas Aeruginosabiofilms

Cascade-Targeted Nanoplatforms for Synergetic Antibiotic/ROS/NO/Immunotherapy against Intracellular Bacterial Infection

Programmable Assembly of Multivalent DNA‐Protein Superstructures for Tumor Imaging and Targeted Therapy

Size and Charge Adaptive Clustered Nanoparticles Targeting the Biofilm Microenvironment for Chronic Lung Infection Management.

Self‐assembly multifunctional DNA tetrahedron for efficient elimination of antibiotic‐resistant bacteria

Inhalable mucin-permeable nanomicelles deliver antibiotics for effective treatment of chronic pneumonia

An Antibiotic Nanobomb Constructed from pH‐Responsive Chemical Bonds in Metal‐Phenolic Network Nanoparticles for Biofilm Eradication and Corneal Ulcer Healing

Novel Self-assembled Organic Nanoprobe for Molecular Imaging and Treatment of Gram-positive Bacterial Infection.

Microenvironment responsive charge-switchable nanoparticles act on biofilm eradication and virulence inhibition for chronic lung infection treatment

Codelivery of synergistic antimicrobials with polyelectrolyte nanocomplexes to treat bacterial biofilms and lung infections

Peptide-Based Nano-Antibiotic Transformers with Antibiotic Adjuvant Effect for Multidrug Resistant Bacterial Pneumonia Therapy

Inflammation-targeted nanoparticle with bacteria forced release of polymyxin B for pneumonia therapy

Integrated Biofilm Dispersion and Virulence Responsiveness for Targeted Treatment of Pseudomonas aeruginosa Infection in Lungs

Inhalable Polymeric Microparticles for Phage and Photothermal Synergistic Therapy of Methicillin-Resistant Staphylococcus aureus Pneumonia

Pseudomonas aeruginosa targeting cascade photodynamic nanoassemblies for efficient antibacterial and anti-inflammatory therapy

Sono‐Triggered Biomimetically Nanoantibiotics Mediate Precise Sequential Therapy of MRSA‐Induced Lung Infection

A Supramolecular Antibiotic Targeting Drug-Resistant Pseudomonas aeruginosa through the Inhibition of Virulence Factors and Activation of Acquired Immunity

Poly(malic acid) Nanoconjugates of Pyrazinoic Acid for Lung Delivery in the Treatment of Tuberculosis

Poly(amino acid)-based drug delivery nanoparticles eliminate Methicillin resistant Staphylococcus aureus via tunable release of antibiotic